March 2010

 

In this Issue

Ongoing SFA Study

Investigators provide overviews of current clinical trials evaluating a variety of techniques for treating superficial femoral artery disease.

Issue

VARICOSE VEIN INTERVENTIONS

Ultrasound-Guided Foam Sclerotherapy

With more studies on the horizon, foam therapy is finding its role in treating venous medical conditions.

By Jose I. Almeida, MD, FACS, RVT

Endovenous Thermal Ablation of the Anterior Accessory Great Saphenous Vein

Clinical aspects of ablating the incompetent anterior accessory great saphenous vein.

By James Laredo, MD, PHD; Byung B. Lee, MD, PHD; AND Richard F. Neville, MD

COVER STORY

Drug-Eluting Balloons in the SFA

Dierk Scheinert, MD, discusses the THUNDER and FemPac trial results and previews new studies that will evaluate drug-coated balloons versus plain old balloon angioplasty.

COMPLETE SE and Other SFA Trials

A look at the ongoing trials of self-expanding stents in the superficial femoral artery.

By Khung Keong Yeo, MD, and John R. Laird Jr, MD

Evaluating the Zilver PTX Stent

Principal investigators discuss the clinical study design and initial results with the Zilver PTX drug-eluting peripheral stent in the SFA.

By Michael D. Dake, MD; Gary M. Ansel, MD, FACC; and Anthony O. Ragheb, PHD

DURABILITY II Trial

A new standard in femoropopliteal artery nitinol stent trial design.

By Krishna Rocha-Singh, MD, FACC, FSCAI, FSVM

The COBRA Trial

How will cryotherapy compare to conventional balloon angioplasty in peripheral vascular interventions?

By Sivavasavi Dinakaran, MD; Praveen Mehta, MD; Daniel Tran, MSC; Emmanouil S. Brilakis, MD; Subhash Banerjee, MD; and Tony S. Das, MD

The STROLL Study

Nitinol self-expandable stent placement for the treatment of obstructive SFA disease.

By Andrew J. Feiring, MD, FACC, FSCAI

The VIBRANT Trial

Comparing bare-nitinol stents to stent grafts in long superficial femoral artery lesions in this unique trial.

By Gary M. Ansel, MD, FACC; Patrick J. Geraghty, MD, FACS; Mark Mewissen, MD; and Michael R. Jaff, DO

The VIPER Trial

With heparin bonded to the surface and a contoured edge, how will stent grafts perform in SFA revascularization?

By Richard R. Saxon, MD, FSIR

The FlexStent Femoropopliteal Self-Expanding Stent

Shortly after the release of preliminary data in New Zealand and Germany, evaluation of the FlexStent system in the United States will begin later this year.

By William A. Gray, MD

The COMPLIANCE 360º Trial

The principal investigator of the COMPLIANCE 360º trial discusses its rationale, study design, and potential therapeutic implications.

By Raymond Dattilo, MD, FACC

The LifeStent Studies

An overview of the trials studying bare-metal stents in the superficial femoral and popliteal artery.

By Thomas Zeller, MD

CODING & REIMBURSEMENT

2010 Fee Schedule Changes

A look at the changes in the Physician Fee Schedule that will affect your practice in 2010.

By Katharine L. Krol, MD

TODAY’S PRACTICE

California PAD Task Force Committee

Michael R. Jaff, DO, discusses the PAD Task Force’s recent initiative to increase awareness of peripheral artery disease.

DEPARTMENTS

INNOVATIONS

A preview of today’s new products

An Interview with Tyrone Collins, MD

Dr. Collins shares perspectives on the progress of medical care in New Orleans after Hurricane Katrina, the focus of this year’s All That Jazz meeting, and the evolution of modern stroke therapy.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.